162 related articles for article (PubMed ID: 32980646)
1. Is benign MS really benign? What a meaningful classification beyond the EDSS must take into consideration.
Ellenberger D; Flachenecker P; Haas J; Hellwig K; Paul F; Stahmann A; Warnke C; Zettl UK; Rommer PS;
Mult Scler Relat Disord; 2020 Nov; 46():102485. PubMed ID: 32980646
[TBL] [Abstract][Full Text] [Related]
2. How common is truly benign MS in a UK population?
Tallantyre EC; Major PC; Atherton MJ; Davies WA; Joseph F; Tomassini V; Pickersgill TP; Harding KE; Willis MD; Winter M; Robertson NP
J Neurol Neurosurg Psychiatry; 2019 May; 90(5):522-528. PubMed ID: 30177509
[TBL] [Abstract][Full Text] [Related]
3. Cognitive impairment, fatigue and depression in multiple sclerosis: Is there a difference between benign and non-benign MS?
Bogaardt H; Golan D; Barrera MA; Attrill S; Kaczmarek O; Zarif M; Bumstead B; Buhse M; Wilken J; Doniger GM; Hancock LM; Penner IK; Halper J; Morrow SA; Covey TJ; Gudesblatt M
Mult Scler Relat Disord; 2023 May; 73():104630. PubMed ID: 36965219
[TBL] [Abstract][Full Text] [Related]
4. The psychosocial and cognitive impact of longstanding 'benign' multiple sclerosis.
Sayao AL; Bueno AM; Devonshire V; Tremlett H;
Mult Scler; 2011 Nov; 17(11):1375-83. PubMed ID: 21677023
[TBL] [Abstract][Full Text] [Related]
5. Natural history of benign multiple sclerosis: Clinical and HLA correlates in a Western Australian cohort.
Fabis-Pedrini MJ; James I; Seewann A; Yau WY; van de Bovenkamp AA; Sanders FRK; Qiu W; Burton J; Mastaglia FL; Carroll WM; Kermode AG
J Neurol Sci; 2018 May; 388():12-18. PubMed ID: 29627005
[TBL] [Abstract][Full Text] [Related]
6. Benign multiple sclerosis: physical and cognitive impairment follow distinct evolutions.
Gajofatto A; Turatti M; Bianchi MR; Forlivesi S; Gobbin F; Azzarà A; Monaco S; Benedetti MD
Acta Neurol Scand; 2016 Mar; 133(3):183-91. PubMed ID: 26009804
[TBL] [Abstract][Full Text] [Related]
7. Benign multiple sclerosis: a need for a consensus.
Glad SB; Aarseth JH; Nyland H; Riise T; Myhr KM
Acta Neurol Scand Suppl; 2010; (190):44-50. PubMed ID: 20586735
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with and long-term outcome of benign multiple sclerosis: a nationwide cohort study.
Crielaard L; Kavaliunas A; Ramanujam R; Olsson T; Hillert J; Stridh P; Kockum I; Manouchehrinia A
J Neurol Neurosurg Psychiatry; 2019 Jul; 90(7):761-767. PubMed ID: 30824631
[TBL] [Abstract][Full Text] [Related]
9. Patient reported outcomes in benign multiple sclerosis.
Hviid LE; Healy BC; Rintell DJ; Chitnis T; Weiner HL; Glanz BI
Mult Scler; 2011 Jul; 17(7):876-84. PubMed ID: 21372114
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC).
Zivadinov R; Cookfair DL; Krupp L; Miller AE; Lava N; Coyle PK; Goodman AD; Jubelt B; Lenihan M; Herbert J; Gottesman M; Snyder DH; Apatoff BR; Teter BE; Perel AB; Munschauer F; Weinstock-Guttman B
BMC Neurol; 2016 Jul; 16():102. PubMed ID: 27416843
[TBL] [Abstract][Full Text] [Related]
11. Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study.
Sartori A; Abdoli M; Freedman MS
J Neurol; 2017 Jun; 264(6):1068-1075. PubMed ID: 28417192
[TBL] [Abstract][Full Text] [Related]
12. Benign multiple sclerosis: a new definition of this entity is needed.
Correale J; Peirano I; Romano L
Mult Scler; 2012 Feb; 18(2):210-8. PubMed ID: 21865415
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life in patients with longstanding 'benign multiple sclerosis'.
Bueno AM; Sayao AL; Yousefi M; Devonshire V; Traboulsee A; Tremlett H
Mult Scler Relat Disord; 2015 Jan; 4(1):31-8. PubMed ID: 25787050
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal follow-up of "benign" multiple sclerosis at 20 years.
Sayao AL; Devonshire V; Tremlett H
Neurology; 2007 Feb; 68(7):496-500. PubMed ID: 17296915
[TBL] [Abstract][Full Text] [Related]
15. Definition, prevalence and predictive factors of benign multiple sclerosis.
Reynders T; D'haeseleer M; De Keyser J; Nagels G; D'hooghe MB
eNeurologicalSci; 2017 Jun; 7():37-43. PubMed ID: 29260023
[TBL] [Abstract][Full Text] [Related]
16. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
[TBL] [Abstract][Full Text] [Related]
17. How long can you keep working with benign multiple sclerosis?
Glad SB; Nyland H; Aarseth JH; Riise T; Myhr KM
J Neurol Neurosurg Psychiatry; 2011 Jan; 82(1):78-82. PubMed ID: 20802029
[TBL] [Abstract][Full Text] [Related]
18. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.
Beiki O; Frumento P; Bottai M; Manouchehrinia A; Hillert J
JAMA Neurol; 2019 Jun; 76(6):665-671. PubMed ID: 30882868
[TBL] [Abstract][Full Text] [Related]
19. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
20. Clinical features and disability progression in multiple sclerosis in Tunisia: do we really have a more aggressive disease course?
Sidhom Y; Damak M; Riahi A; Hizem Y; Mrissa R; Mhiri C; Gouider R
J Neurol Sci; 2014 Aug; 343(1-2):110-4. PubMed ID: 24980939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
